Pathological features-based targeted delivery strategies in IBD therapy: A mini review - 03/06/22
Abstract |
Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by a complex and dysfunctional immune response. Currently, IBD is incurable, and patients with IBD often need to take drugs for life. However, as the traditional systemic treatment strategies for IBD do not target the site of inflammation, only limited efficacy can be obtained from them. Moreover, the possibility of serious side effects stemming from the systemic administration or redistribution of drugs in the body is high when conventional drug formulations are used. Therefore, a targeted drug-delivery system for IBD should be considered. Based on the pathological features related to IBD, the new targeted drug-delivery strategy can directly transfer the drug to the inflammatory site, thus enhancing the accumulation of the drugs and reducing side effects. This article reviews the pathological features of IBD and the application of the IBD-targeted delivery system based on different pathological features, and discusses the challenges and new prospects in this field.
El texto completo de este artículo está disponible en PDF.Graphical Abstract |
Highlights |
• | Summarized the pathological features of IBD. |
• | A review of targeted delivery systems based on pathological features of IBD. |
• | Prospects for research in the field of IBD-TDS. |
Keywords : Inflammatory bowel disease, Targeted drug delivery, Pathological features
Esquema
Vol 151
Artículo 113079- juillet 2022 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?